IDEXX Laboratories, Inc. $IDXX Stock: Robeco Institutional Asset Management B.V. Decreases Position

Key Points

• Robeco Institutional Asset Management cut its IDEXX Laboratories stake by 38% in the third quarter, selling 65,562 shares and retaining 106,831 shares valued at approximately $55.8 million. Institutional investors collectively own 87.84% of the company.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $744.09 price target, although some firms lowered targets or downgraded the stock to “Hold.”
• IDEXX reported quarterly revenue of $1.22 billion and EPS of $4.27, exceeding analyst estimates, while revenue increased 9.7% year over year. Shares recently opened at $566.76, well below their 52-week high of $769.98.

Robeco Institutional Asset Management B.V. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 38.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 106,831 shares of the company's stock after selling 65,562 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.14% of IDEXX Laboratories worth $55,786,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company's stock worth $479,844,000 after purchasing an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company's stock worth $471,335,000 after purchasing an additional 288,471 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of IDEXX Laboratories by 4.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company's stock valued at $322,145,000 after purchasing an additional 23,582 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its holdings in shares of IDEXX Laboratories by 97.3% in the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company's stock valued at $211,146,000 after purchasing an additional 197,808 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on IDXX. KeyCorp started coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They issued a "sector weight" rating for the company. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Barclays lowered their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Finally, Citigroup increased their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $744.09.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $566.76 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company's 50-day moving average price is $532.51 and its 200 day moving average price is $551.58. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The stock has a market cap of $44.65 billion, a price-to-earnings ratio of 39.86, a PEG ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter in the previous year, the business posted $3.50 earnings per share. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares of the company's stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.79% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.